Gos­samer shares take an­oth­er beat­ing as its lead drug fails 2 key clin­i­cal stud­ies, high­light­ing harsh re­views for DP2

Ever since a key DP2 drug at No­var­tis called fe­vip­iprant failed a piv­otal line­up of clin­i­cal stud­ies by the end of last year, a num­ber of an­a­lysts have been sit­ting back wait­ing to see how the same kind of drug would fare at Gos­samer.

Tues­day morn­ing they found out, and it wasn’t pret­ty.

The biotech says their lead drug GB001 failed the pri­ma­ry end­point in their dose-rang­ing asth­ma study as well as all the end­points in a par­al­lel tri­al they ran for chron­ic rhi­nos­i­nusi­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER